Emerging as a promising breakthrough in the fight against obesity, Retatrutide is attracting considerable attention . It combines effects of two established GLP-1 binding agonists, liraglutide, plus an unique glucose-dependent incretin component. Preliminary patient data have demonstrated substantial body loss in individuals with a high BMI , possi